(RTTNews) -  Medical device company NuVasive, Inc. (NUVA: News ) said Friday that it has appointed Michael Lambert as executive vice president and chief financial officer, succeeding Kevin O'Boyle as CFO, effective November 9. The company also announced several other management changes, each effective January 1, 2010.

Most recently, Lambert served as CFO of Advanced Medical Optics, a medical device company focused on technologies used by eye care professionals.

Regarding other management changes, NuVasive said Patrick Miles will be promoted to president of the Americas, and will report to president and chief operating officer Keith Valentine. Miles will oversee NuVasive's global creative product portfolio including marketing and development, clinical research, surgeon education, and sales for the Americas.

Jeffrey Rydin will be promoted to executive vice president of sales, Americas. Rydin will assume direct sales responsibility for the entire Americas' sales force, and will also serve as chairman of NuVasive's newly formed global sales executive committee designed to ensure that NuVasive's global sales and marketing strategy is carried out to maximize results.

Jason Hannon will be promoted to executive VP and general counsel, and he will also continue to be responsible for strategic planning, business development, and legal.
NuVasive added that it is focused on expanding internationally and has added executive VPs for both Asia and Europe that will report to the COO. Takaaki Tanaka has been appointed executive VP of Asia Pacific. The company noted that Tanaka will drive sales and strategic business initiatives in the Asia Pacific region, working from Tokyo, Japan.

Stephan Siemers has been appointed as executive VP of Europe, and he will lead NuVasive's European sales and operations effort from Bremen, Germany.

Chairman and chief executive officer Alex Lukianov said, "As we increase focus on becoming the #4 global spine company and growing to a $1 billion spine franchise, we need a strong management team with the ambition and experience to drive the growth of operations and exemplify NuVasive's culture of Absolute Responsiveness and product innovation."

NUVA is currently trading at $36.77 per share, down 1.66%, on the Nasdaq.

To receive FREE breaking news email alerts for NuVasive, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com